..
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
California
94404
U.S.A.
Phone:
800-GILEAD-5 or 650-574-3000
Fax:
650-522-5800
|
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
Key Contacts:
John C. Martin, PhD, Chairman and Chief Executive Officer
John F. Milligan, PhD, President and Chief Operating Officer
Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer
Kevin Young, Executive Vice President, Commercial Operations
Gregg Alton, Executive Vice President, Corporate and Medical Affairs
Kristen Metza, Senior Vice President, Human Resources
Robin Washington, Senior Vice President and Chief Financial Officer
Susan Hubbard, Vice President, Investor Relations
Amy Flood, Vice President, Public Affairs
Email:
Ownership:
Public
Web Site:
Gilead Sciences, Inc.
Employees:
4,000
Symbol: GILD
|
|
|
Company News |
Experimental Gilead Sciences, Inc. (GILD) Drug Effective in Early-Stage Leukemia Trial
5/16/2013 8:07:15 AM
More...
|
Gilead Sciences, Inc. (GILD) to Present at the Bank of America (BAC) Merrill Lynch 2013 Health Care Conference on Wednesday, May 15
5/15/2013 7:46:01 AM
More...
|
Gilead Sciences, Inc. (GILD)'s HCV Drugs Shine in Trials
5/3/2013 8:18:11 AM
More...
|
Gilead Sciences, Inc. (GILD) Announces First Quarter 2013 Financial Results
5/3/2013 7:49:05 AM
More...
|
Gilead Sciences, Inc. (GILD) Fails FDA Approval for Two HIV Drugs in 4-in-1 Pill
4/29/2013 8:38:51 AM
More...
|
Gilead Sciences, Inc. (GILD) to Release First Quarter 2013 Financial Results on Thursday, May 2, 2013
4/26/2013 6:21:02 AM
More...
|
Gilead Sciences, Inc. (GILD) Supports HarborPath's HIV/AIDS Medication Assistance Pilot Program
4/25/2013 9:54:01 AM
More...
|
Data From Phase 3 Studies of Gilead Sciences, Inc. (GILD)'S Sofosbuvir for Hepatitis C to be Presented at 48th Annual EASL Meeting; Findings Published Online Today in The New England Journal of Medicine
4/24/2013 9:33:39 AM
More...
|
Data From Phase 3 Studies of Gilead Sciences, Inc. (GILD)'s Sofosbuvir for Hepatitis C in the Forefront
4/23/2013 8:36:57 AM
More...
|
Gilead Sciences, Inc. (GILD) Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients
3/26/2013 11:14:45 AM
More...
|
|
|
|